Spinogenix Targets Blindness at Its Root: Synapse Loss

Most eye disease treatments focus on symptoms or slowing damage. Spinogenix Inc. is taking a more aggressive angle: restore the underlying neural connections that are lost.

And its latest preclinical data suggests that idea might actually work.

The Big Idea: Vision Loss Is a Brain Problem Too

Both Glaucoma and Diabetic Retinopathy are often framed as eye conditions. But biologically, they’re closer to neurodegenerative diseases. Why?

• The retina is part of the central nervous system
• It relies on glutamatergic synapses to transmit signals
• These synapses degrade early in disease progression

That last point is critical. By the time neurons die, the damage is already advanced. Synapse loss happens earlier—and may be reversible.

Enter Tazbentetol: A Synapse-Regenerating Drug

Spinogenix’s lead candidate, Tazbentetol, is designed to:

• Trigger neurons to form new synapses
• Restore communication between cells
• Potentially reverse functional decline

This is a first-in-class approach, not neuroprotection, but neuro-restoration.

What the New Preclinical Data Shows?

Presented at the ARVO Annual Meeting, the studies tested tazbentetol in two disease models:

1. Glaucoma Model (Elevated Eye Pressure)

• Induced using microbead injection
• Mimics increased intraocular pressure (IOP)

2. Diabetic Model (Type II Diabetes)

• Genetic (db/db) mice
• Mimics chronic hyperglycemia

Key Findings Across Both Models

1. Neurons Survive

• Retinal ganglion cells (RGCs) were preserved
• These are the neurons whose death leads to blindness

2. Synapses Are Maintained

• Synaptic connectivity in the retina was preserved
• Suggests structural repair—not just protection

3. Optic Nerve Is Protected

• Indicates downstream benefit beyond the retina

4. Vision Function Improves

This is where it gets interesting:

• Increased pERG amplitude → better RGC health
• Reduced pVEP latency → improved signal transmission

Translation: The drug didn’t just change biology—it improved how the visual system works.

The Most Important Detail: It Works Despite Ongoing Disease

This isn’t a prevention model.

• Eye pressure remained elevated in glaucoma mice
• Blood sugar remained high in diabetic mice

Yet the drug still delivered benefits. That suggests:

Tazbentetol may counteract damage even when the disease driver is still active. That’s a big deal if it translates to humans.

Why This Approach Is Different?

Most current therapies:

• Lower eye pressure (glaucoma)
• Control blood sugar (diabetic retinopathy)
• Slow progression

They don’t rebuild what’s already lost. Spinogenix is betting on:

• Synaptic regeneration as a therapeutic strategy
• Treating neurodegeneration at its functional core

Beyond Ophthalmology: A Platform Play

Tazbentetol isn’t limited to eye diseases.

It’s already being studied in:

• Alzheimer’s disease
• Amyotrophic Lateral Sclerosis
• Schizophrenia

The unifying idea: Synapse loss is a common denominator across multiple CNS disorders. If this mechanism holds, the upside is massive.

Reality Check: Still Early

Before this gets overhyped, let’s ground it.

What we know:

• Strong preclinical signal
• Functional improvements observed
• Works across two disease models

What we don’t know:

• Human efficacy
• Long-term safety
• Translational success rate (historically low in CNS)

Preclinical neuroscience has a high failure rate in clinical stages.

The Bottom Line

Spinogenix is pursuing a bold thesis: Don’t just slow degeneration, reverse it by rebuilding synapses. The early data in glaucoma and diabetic retinopathy suggests:

• The biology is plausible
• The functional impact is measurable
• The approach is differentiated

Now comes the hard part: Proving that synapse regeneration works in humans. Because if it does, this isn’t just an eye disease story—it’s a new category of neurotherapeutics.